Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Lu, Zhenduo ^a   Jiao, Dechuang ^a   Qiao, Jianghua ^a   Yang, Sen ^a   Yan, Min ^a   Cui, Shude ^a   Liu, Zhenzhen ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Breast cancer; EMT; MAGE superfamily; mir 200a b; p73; Restin; Tumor metastasis

Indexed keywords

MICRORNA 200A; PROTEIN P73; RESTIN; TRANSCRIPTION FACTOR ZEB1; CYTOPLASMIC LINKER PROTEIN 170; DNA BINDING PROTEIN; HOMEODOMAIN PROTEIN; MICRORNA; MICROTUBULE ASSOCIATED PROTEIN; MIRN200 MICRORNA, HUMAN; NUCLEAR PROTEIN; P73 PROTEIN, HUMAN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR; TRP73 PROTEIN, MOUSE; TUMOR PROTEIN; TUMOR PROTEIN P73; TUMOR SUPPRESSOR PROTEIN; ZEB1 PROTEIN, HUMAN; ZEB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BIOASSAY; BREAST CANCER; CANCER CELL; CELL INVASION ASSAY; CELL MIGRATION ASSAY; CELL MOTILITY; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LUCIFERASE ASSAY; LUNG METASTASIS; MCF 7 CELL LINE; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; WOUND CLOSURE ASSAY; ANIMAL; BREAST TUMOR; CELL MOTION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE; TUMOR INVASION;

LENTIVIRUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DNA-BINDING PROTEINS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MICE; MICRORNAS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR PROTEIN P73; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84929159497     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0370-9     Document Type: Article

References (43)

1. Meek DW, Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett. 2012;324:126-32.
2. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61:5544-51.
3. Hou SY, Sang MX, Geng CZ, Liu WH, Lu WH, Xu YY, et al. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. Arch Med Res. 2014;45:44-51.
4. Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, et al. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat. 2014;145:23-32.
5. Ladelfa MF, Peche LY, Toledo MF, Laiseca JE, Schneider C, Monte M. Tumor-specific MAGE proteins as regulators of p53 function. Cancer Lett. 2012;325:11-7.
6. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 2002;67:705-12.
7. Chapman EJ, Knowles MA. Necdin: a multi functional protein with potential tumor suppressor role? Mol Carcinog. 2009;48:975-81.
8. Haviland R, Eschrich S, Bloom G, Ma Y, Minton S, Jove R, et al. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. PLoS One. 2011;6:e24923.
9. De Faveri LE, Hurst CD, Platt FM, Taylor CF, Roulson JA, Sanchez-Carbayo M, et al. Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer. Br J Cancer. 2013;108:1368-77.
10. Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW. The Diasporin pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis. 2008;25:357-69.
11. Du Q, Zhang Y, Tian XX, Li Y, Fang WG. MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. Oncol Rep. 2009;22:659-65.
12. Selimovic D, Sprenger A, Hannig M, Haikel Y, Hassan M. Apoptosis related protein-1 triggers melanoma cell death via interaction with the juxtamembrane region of p75 neurotrophin receptor. J Cell Mol Med. 2012;16:349-61.
13. Zhu F, Yan W, Zhao ZL, Chai YB, Lu F, Wang Q, et al. Improved PCR-based subtractive hybridization strategy for cloning differentially expressed genes. Biotechniques. 2000;29:310-3.
14. Zhao Z, Lu F, Zhu F, Yang H, Chai Y, Chen S. Cloning and biological comparison of Restin, novel member of Mage superfamily. Sci China C Life Sci. 2002;45:412-20.
15. Hassan M, Mirmohammadsadegh A, Selimovic D, Nambiar S, Tannapfel A, Hengge UR. Identification of functional genes during Fas-mediated apoptosis using a randomly fragmented cDNA library. Cell Mol Life Sci. 2005;62:2015-26.
16. Fu H, Yang G, Lu F, Wang R, Yao L, Lu Z. Transcriptional up-regulation of Restin by all-trans retinoic acid through STAT1 in cancer cell differentiation process. Biochem Biophys Res Commun. 2006;343:1009-16.
17. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112:1776-84.
18. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973-81.
19. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-8.
20. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-90.
21. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19:1438-49.
22. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-73.
23. Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22:1686-98.
24. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429-37.
25. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 2003;5:101-6.
26. Wu Y, Lu F, Qi Y, Wang R, Zhang J, Lu Z, et al. Interaction of Restin with transcription factors. Sci China C Life Sci. 2005;48:256-62.
27. Yan W, Wang WL, Zhu F, Cheng SQ, Li QL, Wang L, et al. Cloning and subcellular localization of apr-1--a new gene of tumor specific antigen family. Ai Zheng. 2005;24:129-34.
28. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593-601.
29. Wei J, Zaika E, Zaika A. p53 family: role of protein isoforms in human cancer. J Nucleic Acids. 2012;2012:687359.
30. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem. 2010;285:14160-9.
31. Wang R, Lu F, Fu H, Wu Y, Yang G, Zhao W, et al. Transcriptional upregulation of Restin by p53. Sci China C Life Sci. 2007;50:88-92.
32. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett. 2014;344:166-73.
33. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846-54.
34. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011;208:875-83.
35. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, et al. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res. 2012;40:499-510.
36. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011;13:317-23.
37. Ridgeway AG, McMenamin J, Leder P. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells. Oncogene. 2006;25:3518-27.
38. Hansen JE, Fischer LK, Chan G, Chang SS, Baldwin SW, Aragon RJ, et al. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res. 2007;67:1769-74.
39. Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014;4:405-14.
40. Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis. 2009;14:336-47.
41. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene. 2007;26:2145-56.
42. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001;12:337-49.
43. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15:2-8.